recombinant oncolytic herpes simplex virus type 1 (r130)

Biologicalexperimental

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06171282Early Phase 1 (Phase 1)Jul 12, 2023Jiao Tong University, Shanghai Yunying Medical Technology
NCT05961111Early Phase 1 (Phase 1)Jun 24, 2023Shanghai Yunying Medical Technology, Yishui Central Hospital of LINYI
NCT05851456Early Phase 1 (Phase 1)Apr 10, 2023Jiao Tong University, Shanghai Yunying Medical Technology
NCT05886075Early Phase 1 (Phase 1)Mar 30, 2023Shanghai Yunying Medical Technology
NCT05830240Early Phase 1 (Phase 1)Mar 27, 2023Fudan University, Shanghai Yunying Medical Technology
NCT05860374Early Phase 1 (Phase 1)Mar 2, 2023Shanghai Yunying Medical Technology, Xuzhou Medical University
NCT05812677Early Phase 1 (Phase 1)Feb 6, 2023Huazhong University of Science and Technology, Shanghai Yunying Medical Technology
NCT05801783Early Phase 1 (Phase 1)Dec 2, 2022Huazhong University of Science and Technology, Shanghai Yunying Medical Technology
Showing 8 of 8 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shanghai Yunying Medical TechnologyFor profit8812022
Huazhong University of Science and TechnologyAcademic/Hospital2012022
Jiao Tong UniversityAcademic/Hospital2012023
Fudan UniversityAcademic/Hospital1012023
Xuzhou Medical UniversityAcademic/Hospital1012023
Yishui Central Hospital of LINYIAcademic/Hospital1012023
6 organizations
Page 1 / 1